By Chris Wack
Actuate Therapeutics shares were 23% lower, at $6.56, after the company said it has priced an underwritten public offering of 2.1 million shares at $7 a share.
The biopharmaceutical company said it has granted the underwriters a 30-day option to buy up to 321,000 additional shares at the public offering price per share, less underwriting discounts and commissions.
The company intends to use the proceeds from the proposed offering for working capital and general corporate purposes.
The offering is expected to close Thursday, subject to the satisfaction of customary closing conditions.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 10, 2025 09:50 ET (13:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.